Literature DB >> 11888869

Frequency of nonsentinel lymph node metastasis in melanoma.

Kelly M McMasters1, Sandra L Wong, Michael J Edwards, Celia Chao, Merrick I Ross, R Dirk Noyes, Vicki Viar, Patricia B Cerrito, Douglas S Reintgen.   

Abstract

BACKGROUND: Completion lymph node dissection (CLND) may not be necessary for some patients because nodal metastasis is rarely detected beyond the sentinel lymph nodes (SLNs). This analysis was performed to determine, among patients with positive SLNs, the rate of nodal metastasis found in nonsentinel nodes (NSNs).
METHODS: This analysis includes patients with positive sentinel nodes, detected by hematoxylin and eosin (H&E) staining or immunohistochemistry (IHC), who then underwent CLND.
RESULTS: This analysis included 274 patients with at least one positive SLN who underwent CLND of 282 involved regional nodal basins. Of the 282 SLN-positive nodal basins, 45 (16%) were found to have positive NSNs in the CLND specimen. Breslow thickness, Clark level, presence of ulceration, histological subtype, presence of vertical growth phase, evidence of regression, presence of lymphovascular invasion, number of positive SLNs, age, sex, and presence of multiple draining nodal basins were not predictive of positive nodes in the CLND specimen. Patients with SLN metastases detected only by IHC had an equal likelihood of having positive NSNs as those patients with positive SLNs on H&E examination.
CONCLUSIONS: No patient population could be identified with minimal risk of non-SLN metastasis. When a positive SLN is identified on either H&E staining or IHC, CLND should be performed routinely.

Entities:  

Mesh:

Year:  2002        PMID: 11888869     DOI: 10.1007/bf02557364

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

Review 1.  The role of radiation therapy in the management of cutaneous melanoma.

Authors:  Charlene E Kan; David B Mansur
Journal:  Melanoma Manag       Date:  2016-02-24

Review 2.  Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.

Authors:  Sabran J Masoud; Jennifer A Perone; Norma E Farrow; Paul J Mosca; Douglas S Tyler; Georgia M Beasley
Journal:  Curr Treat Options Oncol       Date:  2018-09-19

3.  Laparoscopic iliac and iliofemoral lymph node resection for melanoma.

Authors:  Don Hoang; Kurt E Roberts; Edward Teng; Deepak Narayan
Journal:  Surg Endosc       Date:  2012-08-12       Impact factor: 4.584

Review 4.  Surgical treatment of melanoma patients with early sentinel node involvement.

Authors:  Rosemarie E Hardin; Julie R Lange
Journal:  Curr Treat Options Oncol       Date:  2012-09

Review 5.  Lymph nodes and the melanoma surgeon: re-defining a long-term relationship.

Authors:  Mary S Brady
Journal:  Melanoma Manag       Date:  2016-02-24

6.  Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma.

Authors:  David Y Lee; Briana J Lau; Kelly T Huynh; Devin C Flaherty; Ji-Hey Lee; Stacey L Stern; Steve J O'Day; Leland J Foshag; Mark B Faries
Journal:  J Am Coll Surg       Date:  2016-01-29       Impact factor: 6.113

7.  Melanoma controversies: clinical significance of nodal micrometastases and the future of melanoma vaccines.

Authors:  Kelly M McMasters
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

8.  Nonsentinel node metastases in melanoma: do they reflect the biology of the tumor, the lymph node or the surgeon? : Editorial to Accompany Ghaferi et al., ASO-2009-03-0312.R1.

Authors:  Vernon K Sondak
Journal:  Ann Surg Oncol       Date:  2009-08-11       Impact factor: 5.344

Review 9.  Sentinel lymph node biopsy progress in surgical treatment of cancer.

Authors:  T Schulze; A Bembenek; P M Schlag
Journal:  Langenbecks Arch Surg       Date:  2004-06-09       Impact factor: 3.445

10.  [Sentinel lymph node in melanoma].

Authors:  T Meyer; M Möhrle; C Garbe; W Hohenberger
Journal:  Chirurg       Date:  2004-08       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.